Uterine Fibroid Treatment Drugs Market Size, Share | Report 2023-2032
The global uterine fibroid treatment drugs market size was estimated at around USD 1.34 billion in 2022 and it is projected to hit around USD 2.1 billion by 2032, growing at a CAGR of 4.62% from 2023 to 2032.
Uterine fibroid (UF) are the most common benign tumors in women of childbearing age and the world is witnessing rise in prevalence of disease in women which is the key factor driving the market. In February 2022, Contemporary OB/GYN published an article, ‘A Look At the Current State of Uterine Fibroid Care’ which estimates around 70% of women to develop disease by age to 50. In addition, black race has strongest evidence along with 11 other factors such as genetic susceptibility, age, hypertension, premenopausal status, imbalanced diet and overweight are increasing risk of leiomyoma and driving the Uterine Fibroid Treatment Drugs Market.
Every year July is marked as Fibroid Awareness Month and 1st July is dedicated as National Wear White Day to support leiomyoma affected females. Such initiatives aim to raise awareness, emphasis early diagnosis and educate people about the condition. Moreover, in November 2021, Minerva Surgical, Inc. launched the website educating commons about the uterine health. Thus, government and private organizations are actively taking initiatives to raise the awareness in the society and boosting the space growth.
Report Scope of the Uterine Fibroid Treatment Drugs Market
| Report Coverage | Details |
| Market Size in 2022 | USD 1.34 billion |
| Revenue Forecast by 2032 | USD 2.1 billion |
| Growth rate from 2023 to 2032 | CAGR of 4.62% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Myovant Sciences GmbH, Pfizer Inc., Abbvie, Inc., Ferring B.V. AstraZeneca, and Bayer AG among others |
Uterine Fibroid Treatment Drugs Market is segmented by type as:
The space has presence of medications like gonadotropin-releasing hormone (GnRH) agonists and intrauterine devices. Non-hormonal medications include Lysteda, Cyklokapron (Tranexamic acid) and NSAIDs are used for pain management. Moreover, recently approved drugs in space are adding new options for treatment. For instance, in May 2021, FDA approved Pfizer and Myovant Sciences drug Myfembree for treatment of UF associated heavy menstrual bleeding. In addition, there are several drugs under clinical investigation, which are expected to be launched in the coming years, thereby creating lucrative opportunities for market growth. For instance, Kissei Pharmaceutical, Co. Ltd.’s drug candidate KLH-2109 is under phase 3 trials indicated for uterine fibroids patient with menorrhagia and pain.
Key players are undertaking strategic initiatives such as expansion, mergers & acquisitions, new launches, licensing partnerships to increase their market share and further fueling the market growth. For instance, the collaboration between Pfizer, Inc and Myovant Sciences GmbH to bring drug Myfembree in Uterine Fibroid Treatment Drugs Market.
Uterine Fibroid Treatment Drugs Market Segmentations:
| By treatment | By type | By End user |
|
Gonadotropin-releasing hormone (GnRH) agonists Intrauterine devices Non-hormonal medications Others |
Subserosal Fibroids Intramural Fibroids Submucosal Fibroids Pedunculated Fibroids |
Hospitals Ambulatory Surgical Centers Others |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Uterine Fibroid Treatment Drugs Market
5.1. COVID-19 Landscape: Uterine Fibroid Treatment Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Uterine Fibroid Treatment Drugs Market, By Treatment
8.1. Uterine Fibroid Treatment Drugs Market, by Treatment, 2023-2032
8.1.1 Gonadotropin-releasing hormone (GnRH) agonists
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Intrauterine devices
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Non-hormonal medications
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Uterine Fibroid Treatment Drugs Market, By Subserosal Fibroids
9.1. Uterine Fibroid Treatment Drugs Market, by Type, 2023-2032
9.1.1. Subserosal Fibroids
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Intramural Fibroids
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Submucosal Fibroids
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Pedunculated Fibroids
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Uterine Fibroid Treatment Drugs Market, By Hospitals
10.1. Uterine Fibroid Treatment Drugs Market, by End user, 2023-2032
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Ambulatory Surgical Centers
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Uterine Fibroid Treatment Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.1.2. Market Revenue and Forecast, by Type (2020-2032)
11.1.3. Market Revenue and Forecast, by End user (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End user (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.2.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.3. Market Revenue and Forecast, by End user (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End user (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End user (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Type (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End user (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.3.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.3. Market Revenue and Forecast, by End user (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End user (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End user (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Type (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End user (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End user (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End user (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Type (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End user (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.5.3. Market Revenue and Forecast, by End user (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Type (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End user (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Treatment (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Type (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End user (2020-2032)
Chapter 12. Company Profiles
12.1. Myovant Sciences GmbH
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Abbvie, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Ferring B.V. AstraZeneca
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. others
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers